Introduction
In the last few years, clinical indication to allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been extended, and at present, represents the standard of care for selected inherited disorders and highrisk hematological malignancies, and a promising investigational approach for autoimmune diseases and
In brief Progress
Current therapies to prevent and treat graft-versushost disease (GvHD) are insufficient, and new cell and gene therapy approaches are currently being developed. The adoptive transfer of selected antigen-specific lymphocytes decreases the risk of GvHD and promotes graft-versus-infection (GvI). Another approach to reduce the incidence of GvHD is to selectively deplete alloreactive lymphocytes from the graft. New approaches are investigating the depletion of selected T-cell subsets, rather than performing a pan-T-cell elimination. Suicide gene therapy is a novel promising application that exploits alloreactivity against malignant cells with a safe control of GvHD. Transfer of T-cell receptor (TCR) genes into T lymphocytes redirects their specificity and might improve graft-versus-tumor (GvT). Chimeric antigen-receptor genes can be efficiently transferred into T lymphocytes, to confer tumor specificity
Prospects
Gene transfer will need to be efficiently obtained in the absence of functional perturbation of targeted lymphocytes. New cytokine cocktails combined with sophisticated gene transfer technologies enabling site-specific transgene integration will be explored. Automation and measures to reduce costs of clinical trials will be required to allow full clinical exploitation of T-cell-based gene therapy. Phase III clinical trials able to demonstrate the long-term benefits of T-cell-based gene therapy, on morbidity, overall survival and quality of life of treated patients are required.
solid tumors. The efficacy of allo-HSCT in eradicating malignancies relies not only on high-intensity chemotherapy and radiotherapy but also, and most importantly, on the activity of the allogeneic immune system. The transplant procedure is implemented through the following three steps: (1) the conditioning regimen, based on chemo-radiotherapy, devoted to eliminate residual malignant cells and prepare the bone marrow environment to receive donor hematopoietic cells; (2) the infusion of donor (allogeneic) hematopoietic stem cells that will reconstitute the bone marrow in the long term; and (3) the immunological posttransplant activity, exerted by the donor immune system and directed toward recipient cells, including cancer cells.
For the treatment of malignant diseases, the major immunological advantage of allo-HSCT is the graftversus-tumor (GvT) effect: a reaction of the allogeneic immune system against host cancer cells. Unfortunately, alloreactivity is not only directed against malignancies but also against several recipient healthy tissues. This detrimental effect of alloreactivity results in graftversus-host disease (GvHD), the most serious and frequent complication of allo-HSCT, which significantly impairs the quality of life and survival of transplanted patients. 1, 2 To fully exploit the potential of allo-HSCT, three major goals need to be achieved: (1) reduction of the conditioning regimen toxicity; (2) prompt availability of a transplant donor; and (3) development of therapeutic procedures allowing to separate beneficial GvT from detrimental GvHD.
The development and use of new chemotherapeutic drugs with a reduced toxicity profile has already partially limited transplant toxicity, thus allowing this procedure to be extended to aged patients and to patients with comorbidities. 3 Although an increasing number of patients are now eligible to allo-HSCT, most of them lack a conventional human leukocyte antigen (HLA)-identical family donor. Donor availability remains a major hurdle.
This issue fostered the medical community to explore alternative donor sources to provide a suitable donor to every candidate patient. Unrelated volunteer donor banks and cord blood banks partially address this need. However, 30-40% of patients candidated to allo-HSCT fail to find a matched donor. For these cohorts of patients, allo-HSCT from HLA-haploidentical family donors (haplo-SCT) was proposed. 4 Although virtually solving the donor availability issue, haplo-SCT is limited by a very narrow therapeutic index, because of the difficulty in handling the remarkable immunological disparity between donor and host: in haplo-SCT, even low numbers of haploidentical lymphocytes comprise a prohibitive amount of alloreactive cells, able to recognize and react against HLA and minor histocompatibility antigens on host cells, thus resulting in life-threatening GvHD. 5 GvHD (Figure 1 ) is the clinical expression of an immune response resulting from the recognition of host antigens on inflamed host tissues by donor T lymphocytes. [6] [7] [8] Such recognition proceeds through a complex cross-talk between host and donor cells, resulting in 
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Reactive to EBV Figure 1 The three phases model of GvHD pathogenesis. According to the model originally proposed by Ferrara 6 , GvHD pathogenesis proceeds through three different phases: (1) Recipient conditioning by chemotherapy and/or radiotherapy causes tissue damage and the translocation of bacterial products from gut flora (lipopolysaccaride, LPS). This, in turn stimulates the release of proinflammatory cytokines, such as interleukin (IL)-1, IL-6 and TNF-a. Inflammation promotes the migration of activated host APC to secondary lymphoid organs (lymph nodes, Peyer's patches). (2) In secondary lymphoid organs, activated host APCs present alloantigens to donor T lymphocytes and produce polarizing cytokines, such as IL-12. This leads to the proliferation and differentiation of T cells into effectors that produce IL-2 and interferon (IFN)-g. (3) Effector T cells migrate to target tissues (predominantly the skin, gut and liver in acute GvHD, lungs, skin and potentially all tissues in chronic GhVD). Here, they cause target cell apoptosis and a secondary release of proinflammatory cytokines (IL-1, TNF-a), which sustain the reaction.
Graft-versus-host disease
S Mastaglio et al the release of soluble effector molecules and activation of cellular players ultimately leading to tissue damage. [9] [10] [11] Traditionally, the distinction between acute and chronic GvHD was based on the time of onset after transplantation (acute GvHD within 100 days, chronic GvHD 100 days after transplant). More recently, insights into the mechanisms underlying GvHD led to an updated classification based on the specificity of signs and symptoms. 12 The detrimental and beneficial clinical effects of alloreactivity in GvHD and GvT are tightly associated events: strategies able to preserve and enhance posttransplant immune reconstitution and GvT, while preventing or controlling GvHD, are urgently required, especially in the setting of transplantation from HLA-mismatched unrelated donors and family haplo-SCT. In spite of the tremendous effort to prevent or treat GvHD, its outcome still remains highly unsatisfactory. In this context, gene therapy approaches aimed at controlling GvHD while preserving GvT and graftversus-infection (thus enhancing early immune reconstitution) might offer the appropriate answer to an urgent unmet medical need.
Current therapies to prevent and treat GvHD are insufficient and new cell and gene therapy approaches are currently being developed Despite pharmacological prophylaxis, B50% of patients receiving allo-HSCT experience severe GvHD requiring high-dose systemic steroid treatment. The estimated durable complete response rate, defined by the disappearance of all signs of GvHD in response to treatment, is 30-50%. Nonresponders are offered second-line therapy, with different combinations of immunosuppressive agents. The outcome for such patients is poor, the quality of life unsatisfactory and overall survival is usually low (1 year 30% in the largest trials). [13] [14] [15] [16] To overcome these limitations, several novel strategies are currently under investigation. The synergistic effects of mTor (mammalian target of rapamycin) and calcineurin inhibitors 17 or mTor inhibitors and mycophenolate mofetil 18 have been explored in prophylaxis regimens. Similarly, specific anti-T-and B-cell antibodies (such as alemtuzumab, 19 antithymocyte globulin, 20 rituximab 21, 22 ) or antibodies against soluble GvHD effectors (such as infliximab and etanercept; see below) have been tested to prevent GvHD with some success, counterbalanced by a high incidence of severe opportunistic infections and disease relapse. Novel promising targeted treatments aim at interfering with the inflammatory cascade triggered by host alloantigen recognition by donor T cells. In the HLA-identical setting, a recent phase II clinical study showed that the combination of etanercept (an antitumor necrosis factor-a,) and systemic corticosteroids is more effective than standard treatment in controlling GvHD (complete response rates: 69 versus 33%; Po0.001), despite similar rates of infectious complications and long-term outcome. 9 In the context of haplo-HSCT, several approaches based on graft manipulation and cell and gene therapy have been developed.
The adoptive transfer of selected antigen-specific lymphocytes decreases the risk of GvHD and promotes graft-versus-infection
To prevent GvHD while providing a functional T-cell repertoire directed against opportunistic pathogens in allo-HSCT recipients, several investigators have successfully setup protocols to isolate and expand antigenspecific donor lymphocytes recognizing microorganisms, such as cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Aspergillus species. [23] [24] [25] [26] Early studies with gene-marked viral-specific lymphocytes produced optimal clinical results, associated with persistence of gene-modified cells. The successful clinical results obtained with these approaches were counterbalanced by intrinsic limitations of the T-cell repertoire infused, which were insufficient to cope with the wide range of pathogens that threaten immunodeficient patients.
Recently, Leen et al. 27 showed that it is possible to simultaneously isolate and expand bivirus-or trivirusspecific donor T lymphocytes targeting EBV, CMV and adenovirus, by stimulating donor cells with autologous monocytes and EBV cell lines infected with a recombinant adenovirus encoding a CMV structural protein. The genetic modification of antigen-presenting cells to express viral antigens stimulates the expansion of T lymphocytes specific for multiple viruses, thus promoting the generation of a multifunctional T-cell repertoire from a single cell culture. When infused to transplanted patients, bivirus-specific T-cell lines promoted clinically measurable antiviral activity in the absence of GvHD. 27 Several advances were made to reduce the time required for the generation of multiviral-specific lymphocytes, 28 and additional viral antigens can be included into the system, thus providing a wider repertoire. Theoretically, the same approach could be pursued to boost GvT, while providing high-avidity tumorspecific lymphocytes, or lymphocytes directed to minor histocompatibility antigens, selectively expressed in the hematopoietic tissue. 29 Unfortunately, this approach has been less successful to date, possibly due to the difficulty in isolating and expanding these rare cells, and due to the effects of the immunosuppressive/immunoregulatory tumor microenvironment.
Another approach to reduce the incidence of GvHD is to selectively deplete alloreactive lymphocytes from the graft A further improvement toward a wide but safe T-cell repertoire is offered by approaches aimed at the selective depletion of alloreactive cells from the graft. This strategy relies on the in vitro stimulation of donor lymphocytes with host antigen presenting cells (APC), followed by the removal of activated alloreactive lymphocytes before infusion. After stimulation with host cells, alloreactive lymphocytes may be identified by their surface phenotype or preferential accumulation of photoactive dyes, and sorted accordingly. In the first clinical trials, CD25 upregulation by activated cells was Graft-versus-host disease S Mastaglio et al exploited for selective allodepletion. This approach produced mixed clinical responses, presumably due to suboptimal depletion efficiency and/or the concomitant depletion of natural CD25+ regulatory T cells. To increase the efficacy of allodepletion, alternative markers such as CD137 30 and CD95 31 have been proposed. An alternative approach relies on the ability of activated lymphocytes to preferentially accumulate the TH9402 photosensitizer, thus permitting photodepletion of alloreactive cells with high efficiency (to B90% purity). 32, 33 Clinical trials exploring the efficiency of this approach in preventing GvHD are currently ongoing.
New approaches are investigating the depletion of selected T-cell subsets, rather than performing a pan-T-cell elimination Alternative approaches toward GvHD prophylaxis were recently designed on the basis of results obtained with murine allo-HSCT models used to investigate the relative roles of different T-cell subsets in the pathogenesis of GvHD. 10 In mice, both CD4+ and CD8+ T cells have been linked to GvHD. CD8+ cells require alloantigen expression on target cells to elicit both GvHD and GvT. On the other hand, in the CD4+ cell subset, GvHD may occur independently from cognate interactions with target tissues. 34 Upon antigen encounter, T lymphocytes differentiate from naive to memory and effector cells. Several investigators have previously shown that only naive T cells from unprimed donors induce lethal GvHD in major histocompatibility complex-matched and major histocompatibility complex-mismatched allo-HSCT murine models. Conversely, memory T cells do not induce GvHD, but engraft and sustain a significant GvT effect against chronic myeloid leukemia. 35, 36 Chen et al. 37 confirmed these results and extended the observation to central and effector memory T cells. To explain the 'abortive' alloresponse of memory cells, several hypotheses have been postulated, including the restricted T-cell receptor (TCR) repertoire and the limited expansion potential of primed lymphocytes.
Although not yet confirmed in humans, these observations raise questions about the current pan-T-cell suppression modalities of prophylaxis and treatment for GvHD, and suggest the option of targeting specific T-cell subsets through more refined graft manipulation procedures. The infusion of CD8-depleted donor lymphocytes after haplo-SCT produced a low (26%) rate of grade II-IV GvHD. 38 Selective depletion of naive T lymphocytes from the graft has been proposed to reduce or abrogate GvHD while preserving the transfer of a functional memory T-cell repertoire directed to infectious agents and, possibly, malignant cells. 11, 39 An alternative approach relies on the infusion of specific cell types with immunoregulatory effects: clinical phase I-II trials have underlined the efficacy and safety of mesenchymal stem cells in combination with immunosuppressive drugs in the treatment of steroid-resistant GvHD, although subsequent studies, including phase III trials, failed in reproducing initial results. 40, 41 Finally, after encouraging results from studies in murine models, [42] [43] [44] several groups are currently exploring the immunosuppressive activity of regulatory T cells, such as natural CD4+CD25+Foxp3+ and Tr1 lymphocytes, in preventing or controlling GvHD in clinical trials. 45 Suicide gene therapy is a novel promising application that exploits alloreactivity against malignant cells with a safe control of GvHD
The transfer of a suicide gene into donor lymphocytes aims to fully exploit the GvT and graft-versus-infection potential of donor immunity, while selectively controlling GvHD. The expression of a suicide gene allows conditional and selective killing of gene-modified cells: in the majority of cases, the suicide molecule has an enzymatic activity, and is able to convert a prodrug into a toxic metabolite. If the suicide gene is expressed by donor lymphocytes infused to transplanted patients, the administration of the prodrug during GvHD activates the suicide machinery and selectively eliminates genemodified cells leading to GvHD control. This has been shown to occur without interfering with the natural process of immune reconstitution promoted by the graft. 46 The first and, until now, the only suicide gene tested and validated in clinical trials, is the herpes simplex virus thymidine kinase (TK) gene that confers ganciclovir sensitivity to transduced cells. Clinical trials involving 4120 transplanted patients showed the safety of the TK-based gene therapy approach. In all published trials, lymphocytes were transduced with retroviral vectors (RVs), encoding TK and a selection gene. A transduction efficiency of 30-40% was easily achieved and transduced cells were sorted to allow the infusion of a cell population homogenously expressing the suicide phenotype. Strikingly, all cases of GvHD occurring after the infusion of TK cells were completely controlled, 47 and in the majority of cases, the only administration of the prodrug was sufficient to abrogate GvHD, indicating the efficacy of the suicide gene/prodrug system. TK-cell infusions proved feasible in patients with disease recurrence after HLA-identical SCT. GvT activity was observed and directly correlated with in vivo expansion of TK lymphocytes. 48 Long-term persistence of polyclonal TK cells was observed in several trials, 49 suggesting that TK cells could mediate long-term immunosurveillance against tumors. In a phase I-II multicenter trial, TK cells were infused to patients with high-risk leukemia after haplo-SCT, to induce early immune reconstitution and promote GvT, while selectively controlling GvHD. A total of 50 patients were transplanted with T cell-depleted hematopoietic stem cells from a haploidentical donor and, 1 month after transplant, 28 patients received donor lymphocytes genetically modified by the SFCMM3 RV and immunoselected for the expression of a surface marker (a truncated form of the low-affinity nerve growth factor receptor). The gene transfer procedure proved highly feasible and efficient (average purity of TK cells infused: 91%). A total of 22 patients obtained early immune reconstitution documented by 4100 per ml circulating T lymphocytes observed as early as in the first 3 months Graft-versus-host disease S Mastaglio et al after haplo-SCT. Acute GvHD (grade I-IV) and chronic GvHD occurred in 10 and 1 patients, respectively, and were always controlled by the suicide gene induction. 46 This study confirmed the safety and potential benefit of the gene transfer technology, integrated with allo-HSCT, in improving survival of treated patients, as shown by the abrogation of late transplant-related mortality, extremely frequent after T cell-depleted haplo-SCT. 50 The following three major limitations have emerged in clinical trials with TK cells:
(1) An alternative splicing site in the TK gene, resulting in the expression of a nonfunctional TK molecule in a minority of transduced cells. New TK gene variants, devoid of splicing sites were developed and tested. 51, 52 (2) The need for ganciclovir administration to treat CMV, resulting in the unwanted elimination of TK cells. This issue is in part overcome by the availability of alternative drugs, and largely counterbalanced by the antiviral immune responses promoted by TK-cell infusions. (3) The immunogenicity of viral-derived TK protein.
Of clinical relevance is that the development of a cytotoxic immune response against TK, that leads to the elimination of TK-engineered donor lymphocytes, completely depends on the infusion time point after SCT, and namely on the level of patient immune reconstitution at this time point. 53, 54 When TK cells are infused to immunosuppressed patients, they are well tolerated and persist in the long term. 53, 54 To overcome the immunogenicity issue, novel suicide genes coding for human proteins have been recently identified and tested at the preclinical level. Recently, a chimeric suicide gene incorporating the death domains of caspase 9 (iCasp9) has been developed. The molecule is fused to a modified human FK506-binding protein. The exposure to a nontoxic chemical dimerizer induces 490% apoptosis of gene-modified cells. Human lymphocytes have been efficiently transduced by RVs 55 and Piggybac transposones 56 to express iCasp9. Tey et al. investigated the suitability of expressing iCasp9 in allodepleted T cells. After allodepletion, donor T cells could be efficiently transduced (average transduction efficiency: 53%) by an RV encoding iCasp9 and expanded in vitro. Engineered cells retained antiviral specificity and functionality, and contained a subset of functional T-regulatory cells. Although transgene expression was transiently downregulated in quiescent T cells, possibly due to the activation-dependent activity of the longterminal repeat promoter, iCasp9 remained an efficient suicide gene, as expression was rapidly upregulated in activated T cells. 55 A clinical trial investigating the safety and efficacy of iCasp9-transduced allodepleted lymphocytes is currently starting.
Transfer of TCR genes into T lymphocytes redirects their specificity and might improve GvT
Although suicide gene therapy aims at controlling the toxic effects of alloreactivity, alternative gene transfer approaches have been proposed to increase the GvT potential of donor lymphocytes. These approaches aim to overcome the major hurdles limiting the feasibility and efficacy of adoptive cellular immunotherapy with tumor-specific lymphocytes, such as: (1) the low number of high-avidity cytotoxic T lymphocytes (CTLs) specific for tumor-associated antigens due to central tolerance to self-antigens and (2) the difficulty in expanding these cells in a timeframe compatible with rapidly growing tumors. To overcome these difficulties, high-avidity TCR isolated from tumor-specific CTLs may be genetically transferred into human T lymphocytes to redirect their specificity toward autologous tumor cells. In a recent clinical trial, the infusion of lymphocytes retrovirally transduced to express a tumor-specific TCR caused melanoma regression in 9 of 32 patients, treated for metastatic melanoma (follow-up: 4-17 month). 57 Major difficulties limiting this first trial were related to the low persistence of infused cells and low levels of transgene expression. 58 In the context of allo-HSCT, Falkenburg and colleagues showed that high-avidity TCR specific for hemopoietic-restricted minor histocompatibility antigens may be efficiently transferred into donor lymphocytes to promote GvT. When the minor-specific TCR is transferred by an RV into CMV-specific lymphocytes, dual specificity is demonstrated, and it may be speculated that frequent encounter of T cells with the viral antigen might ensure prolonged T-cell survival in vivo 59 and possibly counteract the detrimental effects of the tumor microenvironment on T-cell function. Indeed, studies in mice with dual TCR transgenic lymphocytes showed that tolerization of one TCR could be rescued by signaling through the second TCR. 60 A major limitation of TCR gene transfer is related to the coexpression of the exogenous and endogenous TCR within the same cells. Mispairing between endogenous and exogeneous a-and b-TCR chains may result in autoreactive specificities. 61 Moreover, the limited availability of accessory molecules, required to express the TCR on the cell membrane, might reduce the avidity of transferred T cells. Current strategies, aimed at promoting preferential pairing and expression of exogenous TCR, and at reducing the rate of mispairing, exploit murine TCR constant regions-dominantly expressed in human lymphocytes but possibly immunogenic-and molecular modifications of the TCR constant regions (such as inclusion of a set of additional cysteins to promote disulfide bonds) finalized to increase their reciprocal affinity. [62] [63] [64] This strategy aims at increasing the proportion of gene-modified T cells expressing the exogenous tumor-specific TCR at high levels, while avoiding the production of functionless and potentially autoreactive T cells.
Chimeric antigen-receptor genes can be efficiently transferred into T lymphocytes to confer tumor specificity T lymphocytes may be genetically equipped to recognize surface antigens expressed by tumor cells without the requirement for major histocompatibility complex restriction of antigenic peptides. This strategy relies on chimeric antigen receptors (CARs), synthetic molecules characterized by an extracellular antigen-binding segment composed of the antigen-binding domain of Graft-versus-host disease S Mastaglio et al a tumor-specific monoclonal antibody in the form of a single chain linked to an intracellular signaling region such as the z-chain of the TCR/CD3 complex. CAR genes may be introduced into T cells by several approaches such as DNA electroporation, 65 or with more efficient methods such as viral vectors 66 or Sleeping Beauty transposon/transposase systems. 67 When CAR-expressing T cells encounter antigen-positive tumor cells, antigen binding triggers the signaling endodomain, ultimately leading to T-cell activation. CAR-expressing T lymphocytes exert their cytolytic activity through secretion of perforine/granzyme-B and through interferon-g release.
Several molecules, expressed on the cell surface of various tumors, have been identified as suitable targets for CAR-based immunotherapy. 68, 69 The CAR-based approach seems ideal for targeting B-cell malignancies, as surface molecules, such as CD20, have been validated as relevant therapeutic targets of monoclonal antibodies in follicular, diffuse large-cell and mantle-cell lymphomas. Antigen-specific domains isolated from monoclonal antibodies to CD19 have been used to engineer T cells to target B-cell leukemia, and after encouraging preclinical results, phase 1 clinical trials based on the adoptive transfer of CAR-modified T cells were initiated. The first clinical trials involving CAR-engineered lymphocytes produced suboptimal results, mainly due to short persistence of genetically modified cells in vivo. 70 This may be attributed to protocols of T-cell manipulation, that mainly generated gene-modified lymphocytes with an effector/effector memory phenotype, characterized by a low expansion potential, and to the inability of the CAR molecule to trigger sufficient survival and expansion signals. The latter observation guided the development of second-generation CARs, which carry, together with the CD3 domain, specific costimulatory molecules, such as CD28, ICOS, CD134 or CD137. 69 Recently, Brenner and colleagues showed that the transfer of a CAR directed to the diasialganglioside GD2, expressed by neuroblastoma in EBV-specific CTLs, results in tumor regression in 50% of treated patients. The high efficacy of this approach is possibly due to optimal costimulation resulting from the engagement of the native TCR by EBV targets in vivo. A further improvement of the CAR-gene transfer approach may rise by strategies that combine the genetic transfer of tumor-specific CARs, with the transfer of molecules that preferentially target lymphocytes to tumor sites. Di Stasi et al. 71 recently showed in a xenograft model that the expression of CCR4 enhances responses to Hodgkin's disease promoted by T cells expressing a CD30-reactive CAR.
Conclusions
Cell and gene therapy approaches currently investigated for selective GvHD control are summarized in Figure 2 . The potency of cellular adoptive immunotherapy against cancer has been shown by persistent and complete clinical responses obtained with allo-HSCT, followed by the adoptive transfer of donor T lymphocytes. 72 This has been reinforced by the encouraging clinical responses observed with adoptive transfer of tumour-specific CTLs in cancer patients. 73, 74 Major hurdles limiting adoptive T-cell therapy relate to toxicity (that is, GvHD in allo-HSCT) and efficacy (that is, difficulty in expanding rare, high-avidity tumour-specific CTLs). Recent insights into T-cell biology and technological advances in gene transfer technologies have enabled these hurdles to be overcome, and further increase the efficacy of adoptive immune therapy. 
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An advantage of T-cell-mediated immunity compared with standard therapy, including monoclonal antibodies, is the continuous generation of antigen-specific effector and memory T cells. In the presence of chronic infections or cancer, these cells both elicit a proper response to pathogens and produce surveillance for recurrence or minimal residual disease. In cancer patients treated with adoptive cellular immunotherapy, prolonged persistence of adoptively transferred lymphocytes correlates with a favorable clinical outcome.
Several groups are currently exploiting gene transfer technologies to increase the life span and potential expansion of infused lymphocytes, 75 thus producing genetically modified tumor-specific T cells capable on one hand to target and eliminate tumor cells in vivo (effectors), and, on the other, to provide a continuous and persistent surveillance against the reappearance of tumor cells (central memory cells). This goal might be either achieved by expressing homeostatic cytokines, 76 or cognate receptors 77 into T lymphocytes, or by gene transfer and expansion of selected T-cell sub-populations with retroviral and lentiviral vectors. 78 We showed that a potent activation with cell-sized beads conjugated with antibodies directed to CD3 and CD28 recruits in cell cycle, thus facilitating retroviral transduction of naive and central memory (T CM ) lymphocytes. When transduced to express a suicide gene, and cultured with a combination of IL-7 and IL-15, gene-modified cells showed a preserved central memory functional phenotype, proved able to expand and selfrenew, were resistant to activation-induced cell death and were highly alloreactive in vivo. Most importantly, the suicide phenotype allowed full control of GvHD in immunodeficient mice, 52 thus suggesting that exploitation of a safe and controlled alloreactivity might be achieved through suicide gene therapy. Suicide gene therapy is, to date, the most extensive clinical application of T cell-based gene therapy. In several phase I-II studies conducted in Europe, the United States and Asia, this approach proved feasible, safe and effective in promoting a dynamic and patient-specific modulation of alloreactivity.
Prospects
At present, gene transfer technologies allow to stably express several genes with high efficiency in T lymphocytes, thus increasing the efficacy/toxicity index of allogeneic T lymphocytes in the context of allo-HSCT. A major challenge we will have to face relates to the possibility to express such genes in the absence of unwanted functional perturbations of targeted lymphocytes. This will be possibly achieved through a combination of proper cytokine cocktails and more sophisticated gene transfer technologies, such as zinc-finger nucleases, enabling transgene integration in preselected genomic sites. 79, 80 As the level of technological complexity increases, possibly enhancing the potency of T cell-based gene transfer, we will need to face the difficult issue of economic sustainability of gene therapy. Paradoxically, this will be probably achieved through the development of phase III clinical trials, able to demonstrate the long-term benefits of T cell-based gene therapy on morbidity, overall survival and quality of life of treated patients, thus enabling proper cost/benefit assessments. To this purpose, every effort toward an increased level of automation will be highly rewarded. A multicenter, randomized phase III clinical study has started in Europe to verify the impact of suicide gene therapy in improving overall survival of cancer patients after haplo-HSCT. If successful, this trial will lead to the registration of a gene therapy approach as a cell-based medicinal product, a critical step for gene therapy to establish finally its role as a major therapeutic tool.
